← Eichor
Study identifier: NCT05253560 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Prodromal Parkinsonian Features in GBA1 Mutation Carriers

Condition: Gaucher Disease, Type 1 · Healthy  ·  Sponsor: Shaare Zedek Medical Center

PhaseN/A
Planned participants600
Who can joinAll sexes, 40 Years to 75 Years
Healthy volunteersYes

About this study

Objective of the trial. To define a sub-population which is at increased risk of developing Parkinson, beyond the fact of carrying Gaucher; in this sub-population the investigators shall conduct a comprehensive evaluation that includes a variety of non-invasive tests, whose purpose is to evaluate the state of the pre- Parkinson's disease signs, signs which can appear, even twenty years before the appearance of the disease, and also to compare them to a group of diagnosed Gaucher patients and a group of healthy people who are not carriers of Gaucher disease. A group of those carriers will be available for trial or for treatment, if there will be a medicine for the prevention of the development of Parkinson, obtainable.

This description comes directly from the study's public registry record.

Talk to the study team

Ari Zimran, MD  ·  +972-509149149  ·  azimran@gmail.com

Michal Becker- Cohen, M.Sc.  ·  +972-504606310  ·  michalbec@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Michal Becker- CohenJerusalem, Please Select..., IsraelRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05253560